MI-3454

CAS No. 2134169-43-8

MI-3454( —— )

Catalog No. M35130 CAS No. 2134169-43-8

MI-3454 is an orally active, selective and potent inhibitor of Menin-MLL1 interaction that inhibits the proliferation and induces differentiation of acute leukemia cells with MLL1 translocation or NPM1 mutation.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 301 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    MI-3454
  • Note
    Research use only, not for human use.
  • Brief Description
    MI-3454 is an orally active, selective and potent inhibitor of Menin-MLL1 interaction that inhibits the proliferation and induces differentiation of acute leukemia cells with MLL1 translocation or NPM1 mutation.
  • Description
    MI-3454 is an orally active, highly potent and selective menin-MLL1 interaction inhibitor with an IC50 of 0.51 nM. MI-3454 inhibits proliferation, induces differentiation and complete remission or regression of leukemia in mouse models of MLL1-rearranged or NPM1-mutated leukemia through downregulation of key genes involved in leukemogenesis.
  • In Vitro
    Cell Proliferation Assay Cell Line:Murine bone marrow cells transformed with MLL-AF9 or Hoxa9/Meis1 Concentration:0.001, 0.01, 0.1, 1, 10 μM Incubation Time:7 days Result:Demonstrated strong reduction of cell proliferation.RT-PCR Cell Line:Human leukemic cell lines MV-4-11 cells or MOLM13 Concentration:50 nM Incubation Time:6 days Result:Led to downregulated expression of HOXA9 and MEIS1 and expression level of other MLL fusion target genes, including MEF2C, DLX2, HOXA10, PBX3, and FLT3.
  • In Vivo
    Animal Model:8- to 10-week-old female NSG mice (MV-4-11 xenotransplantation model of MLL leukemia) Dosage:120 mg/kg Administration:Orally; one or twice daily for 7 consecutive daysResult:A once-daily treatment was sufficient to block leukemia progression. Animal Model:Female CD-1 mice Dosage:100 mg/kg (PO) or 15 mg/kg (IV) (Pharmacokinetic Analysis) Administration:PO or IV Result:Had a T1/2 of 3.2 hours, a Cmax of 4698 mg/mL for PO. Had a T1/2 of 2.4 hours, a CL of 2375 mL/hours?kg, and a Vss of 5358 mL/kg for IV.
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Histone Methyltransferase
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2134169-43-8
  • Formula Weight
    636.73
  • Molecular Formula
    C32H35F3N8OS
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 31.25 mg/mL (49.08 mM; Ultrasonic )
  • SMILES
    CNc1nc(NC2CCN(Cc3ccc4n(CC56CC(C5)(C6)NC=O)c(cc4c3C)C#N)CC2)c2cc(CC(F)(F)F)sc2n1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Szymon Klossowski, et al. Menin Inhibitor MI-3454 Induces Remission in MLL1-rearranged and NPM1-mutated Models of Leukemia. J Clin Invest. 2020 Feb 3;130(2):981-997.?
molnova catalog
related products
  • Cucurbitacin S

    Cucurbitacin S is isolated from cucurbitaceae with anticancer and anti-inflammatory activities.

  • Histrelin acetate

    Histrelin acetate is a nonapeptide analog of gonadotropin-releasing hormone (GnRH) with added potency. It acts on particular cells of the pituitary gland called gonadotropes when present in the bloodstream. Histrelin stimulates these cells to release luteinizing hormone and follicle-stimulating hormone. Thus it is considered a gonadotropin-releasing hormone agonist or GnRH agonist.

  • BecloMethasone

    BecloMethasone is a prototype glucocorticoid receptor agonist.?It is used topically as an anti-inflammatory agent and in aerosol form for the treatment of asthma.